{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:12:36Z","timestamp":1769206356892,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s10147-019-01567-y","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T14:03:41Z","timestamp":1572617021000},"page":"502-507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study"],"prefix":"10.1007","volume":"25","author":[{"given":"Takashi","family":"Shibutani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4031-8091","authenticated-orcid":false,"given":"Shoji","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasumi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoatsu","family":"Jimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Kitai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaya","family":"Shiozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamotsu","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,1]]},"reference":[{"key":"1567_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/annonc\/mdx011","volume":"28","author":"A Karam","year":"2017","unstructured":"Karam A, Ledermann JA, Kim JW et al (2017) Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. Ann Oncol 28:711\u2013717","journal-title":"Ann Oncol"},{"key":"1567_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ygyno.2008.09.034","volume":"112","author":"F Muggia","year":"2009","unstructured":"Muggia F (2009) Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol 112:275\u2013281","journal-title":"Gynecol Oncol"},{"key":"1567_CR3","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194\u20133200","journal-title":"J Clin Oncol"},{"key":"1567_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trop\u00e9 CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943\u2013953","journal-title":"N Engl J Med"},{"key":"1567_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe S, Hook J, Nankivell M et al (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386:249\u2013257","journal-title":"Lancet"},{"key":"1567_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","volume":"59","author":"A Fagotti","year":"2016","unstructured":"Fagotti A, Ferrandina G, Vizzielli G et al (2016) Phase III randomised clinical trial comparing primary surgery vs. neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer 59:22\u201333","journal-title":"Eur J Cancer"},{"key":"1567_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.05.017","volume":"64","author":"T Onda","year":"2016","unstructured":"Onda T, Satoh T, Saito T et al (2016) Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III\/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer 64:22\u201331","journal-title":"Eur J Cancer"},{"key":"1567_CR8","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","volume":"19","author":"I Vergote","year":"2018","unstructured":"Vergote I, Coens C, Nankivell M et al (2018) Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol 19:1680\u20131687","journal-title":"Lancet Oncol"},{"key":"1567_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1634\/theoncologist.6-suppl_3-30","volume":"6","author":"L Norton","year":"2001","unstructured":"Norton L (2001) Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 6:30\u201335","journal-title":"Oncologist"},{"key":"1567_CR10","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","volume":"374","author":"N Katsumata","year":"2009","unstructured":"Katsumata N, Yasuda M, Takahashi F et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:1331\u20131338","journal-title":"Lancet"},{"key":"1567_CR11","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","volume":"14","author":"N Katsumata","year":"2013","unstructured":"Katsumata N, Yasuda M, Isonishi S et al (2013) Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 14:1020\u20131026","journal-title":"Lancet Oncol"},{"key":"1567_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ygyno.2016.04.539","volume":"142","author":"DA Becker","year":"2016","unstructured":"Becker DA, Thomas ED, Gilbert AL et al (2016) Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma. Gynecol Oncol 142:25\u201329","journal-title":"Gynecol Oncol"},{"key":"1567_CR13","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00280-016-3187-3","volume":"78","author":"T Ebata","year":"2016","unstructured":"Ebata T, Yunokawa M, Bun S et al (2016) Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas. Cancer Chemother Pharmacol 78:1283\u20131288","journal-title":"Cancer Chemother Pharmacol"},{"key":"1567_CR14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/jjco\/hyx118","volume":"47","author":"T Yoshihama","year":"2017","unstructured":"Yoshihama T, Nomura H, Iwasa N et al (2017) Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer. Jpn J Clin Oncol 47:1019\u20131023","journal-title":"Jpn J Clin Oncol"},{"key":"1567_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2013","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2013) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"1567_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl 48:452\u2013458","journal-title":"Bone Marrow Transpl"},{"key":"1567_CR17","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1056\/NEJMoa1505067","volume":"374","author":"JK Chan","year":"2016","unstructured":"Chan JK, Brady MF, Penson RT et al (2016) Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 374:738\u2013748","journal-title":"N Engl J Med"},{"key":"1567_CR18","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","volume":"15","author":"S Pignata","year":"2014","unstructured":"Pignata S, Scambia G, Katsaros D et al (2014) Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15:396\u2013405","journal-title":"Lancet Oncol"},{"key":"1567_CR19","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.3802\/jgo.2018.29.e96","volume":"29","author":"MX Lee","year":"2018","unstructured":"Lee MX, Tan DS (2018) Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen? J Gynecol Oncol 29:e96","journal-title":"J Gynecol Oncol"},{"key":"1567_CR20","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA et al (2011) Gynecologic oncology group, incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473\u20132483","journal-title":"N Engl J Med"},{"key":"1567_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2016.09.036","volume":"70","author":"R Rouzier","year":"2017","unstructured":"Rouzier R, Gouy S, Selle F et al (2017) Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial. Eur J Cancer 70:133\u2013142","journal-title":"Eur J Cancer"},{"key":"1567_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/jso.25187","volume":"118","author":"S Komiyama","year":"2018","unstructured":"Komiyama S, Kugimiya T, Kubushiro K (2018) Safety and efficacy of neoadjuvant chemotherapy containing bevacizumab and interval debulking surgery for advanced epithelial ovarian cancer: a feasibility study. J Surg Oncol 118:687\u2013693","journal-title":"J Surg Oncol"},{"key":"1567_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00404-016-4256-x","volume":"295","author":"X Xu","year":"2017","unstructured":"Xu X, Deng F, Lv M et al (2017) The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc\u2013IV high-grade serous ovarian cancer. Arch Gynecol Obstet 295:451\u2013458","journal-title":"Arch Gynecol Obstet"},{"key":"1567_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ygyno.2014.09.002","volume":"135","author":"PE Colombo","year":"2014","unstructured":"Colombo PE, Labaki M, Fabbro M et al (2014) Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer. Gynecol Oncol 135:223\u2013230","journal-title":"Gynecol Oncol"},{"key":"1567_CR25","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1097\/IGC.0000000000001108","volume":"27","author":"G Bogani","year":"2017","unstructured":"Bogani G, Matteucci L, Tamberi S et al (2017) The impact of number of cycles of neoadjuvant chemotherapy on survival of patients undergoing interval debulking surgery for stage IIIC-IV unresectable ovarian cancer results from a multi-institutional study. Int J Gynecol Cancer 27:1856\u20131862","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-019-01567-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T01:01:14Z","timestamp":1604106074000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-019-01567-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1567"],"URL":"https:\/\/doi.org\/10.1007\/s10147-019-01567-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,1]]},"assertion":[{"value":"26 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of the Hyogo Cancer Center (Hyogo, Japan).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}